Overview

QGel was a biomedical technology company specialized in organoid applications and solutions. QGel technology was acquired by a Precision Cancer Technologies Inc. (PCT) in 2021. The company raised CHF 25 million to develop the QGel technology consisting of a portfolio of 5 international patent families. QGel's hydrogel technology mimics the microenvironment surrounding cells inside the human body. This feature facilitates growing patient cells from biopsies in a lab without losing the unique biological characteristics of the patient. With patient samples grown in a lab, many potential anti-cancer therapies can be tested on patient cancer avatars, ex vivo, to observe how each tumor clone responds to each therapy option, giving oncologists insight to expected patient response.